Latest Breaking News On - Targeted radionuclide therapy - Page 7 : comparemela.com

Global Roundup: UCB Snaps Up Rare Disease Company Zogenix

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

United kingdomCharl van zylEisbach bio gmbPersongen biotherapeuticsPoolbeg pharmaThalys medlabIsotopen technologienMd anderson cancer centerZogenix incAvacta groupChina angel pharmaceuticalsThalys groupGenetic analysi technologyEurope internationalKings collegeMd anderson therapeutics division

ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n c a 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the

United statesBen orzelekValeria fisherKostenloser wertpapierhandelThorvardur ragnar halfdanarsonSteffen schusterJulia hofmann susanne karlssonUdoj vetterSolucin gmbPhilipe harrisCorporate communicationsDistrict courtTrophic communicationsDeutsche bank freiburgTechnologies munichCancers symposium

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Reinhard zeidlerBen orzelekLu endolucinbetaDeutsches forschungszentrumValeria fisherSteffen schusterJulia hofmann susanne karlssonUmwelt gmbNuclear medicineCorporate communicationsHelmholtz associationTrophic communicationsHelmholtz munichTechnologies munichProject leaderTargeted radionuclide therapy

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme | More News

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

Reinhard zeidlerSteffen schusterLu endolucinbetaUmwelt gmbDeutsches forschungszentrumNuclear medicineHelmholtz associationHelmholtz munich sign cooperation agreementClinical developmentRadiopharmaceutical therapyTreat glioblastoma multiformeHelmholtz munichGermanyi januaryTechnologies munichProject leaderTargeted radionuclide therapy

ITM Isotope Technologies Munich SE: ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

Investigator-initiated multicenter Phase I study in glioblastoma with CAXII-targeting, 177Lu radiolabeled antibody Fab fragment (LuCaFab) in preparation, led by University of Münster as the sponsor

Reinhard zeidlerBen orzelekLu endolucinbetaDeutsches forschungszentrumValeria fisherKostenloser wertpapierhandelSteffen schusterJulia hofmann susanne karlssonUmwelt gmbNuclear medicineCorporate communicationsHelmholtz associationTrophic communicationsHelmholtz munichTechnologies munichProject leader